In addition, specifically blocking OPN receptors (integrins/CD44) and inhibiting transcription factors that initiate OPN expression may also be a strategy for the treatment of ARDS in the future [30,31]. The gene discussed is SPP1; the disease is acute respiratory distress syndrome.